EnClear Therapies
CAMBRIDGE, MA · Medical Device · 9 employees
EnClear Therapies is a Cambridge (USA) based life sciences company developing a device-based therapy to aid in the treatment of neurodegenerative disease and delivery and monitoring of cerebrospinal fluid (CSF). EnClear’s proprietary therapeutic platform focuses on removing toxic proteins from the CSF. The company’s first products will target improving the lives of patients with Amyotrophic Latera
Funding history
- Series seed — $718K — Mar 2024
- Series series a — $10.0M — Feb 2020
Recent signals
- Sep 04, 2024: Raised funding
- Mar 01, 2024: Raised $718K in Series seed
- Feb 19, 2020: Raised $10.0M in Series series a
See plans & pricing → Track EnClear Therapies’s funding, hiring, and signals — with verified contacts — on Fundz.